+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07483385

Evaluating Lusutrombopag for Safety and Effectiveness After Stem Cell Transplant in Patients with Blood Disorders

Led by The General Hospital of Western Theater Command · Updated on 2026-03-25

45

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the clinical effectiveness and safety of Lusutrombopag in helping platelet recovery after allogeneic hematopoietic stem cell transplantation in patients with blood disorders. This is a prospective, single-center, open-label clinical trial led by The General Hospital of Western Theater Command. The study focuses on patients undergoing transplantation and aims to assess platelet remodeling and engraftment rates. Participants will receive Lusutrombopag starting at 3 mg once daily. Treatment lasts for up to two weeks until complete response is achieved, discontinued after 14 days of continuous therapy, or if certain stopping criteria are met. After this treatment period plus an additional 14 days, patients will be monitored to determine if ongoing medication or changes in regimen are needed. During the study, researchers will track the platelet accumulation engraftment rate 21 days after transplantation as the primary outcome. Secondary outcomes include measuring the median time to platelet and neutrophil engraftment within 30 days post-transplant. Participants will be regularly assessed for clinical efficacy and safety outcomes throughout and after the treatment period. The total duration includes treatment, observation, and follow-up to ensure comprehensive monitoring of patient responses.

CONDITIONS

Brief Title

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

Research Team

L

Lei Ma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here